Skip to main content

Table 5 Best response after salvage PRRT

From: Salvage PRRT with 177Lu-DOTA-octreotate in extensively pretreated patients with metastatic neuroendocrine tumor (NET): dosimetry, toxicity, efficacy, and survival

Authors patients n= Number of PRRT cycles Median Follow-Up [months] CR/PR/MRa SDb PDc
This study 35 5–8 25 1 (3.1) 26 (81.6) 5 (15.3)
Sabet et al. [12] 33 5–8 23 7 (21.2) 14 (42.4) 11 (33.3)
van der Zwan et al. [14] 168 5–8 30.4 26 (15.5) 100 (59.5) 33 (19.6)
  1. aCR/PR/MR Complete/Partial/Minor Response, bSD Stable Disease, cPD Progressive Disease
  2. Data is presented as number (%) of patients. Assessment of best response was based on RECIST 1.1 in the current study and in [14] and on SWOG criteria in [12]; 3 and 9 patients were excluded in the current study and in [14], respectively